Physician profile
Andrew S Korman
NPI 1780833343
$2,898.25
in general payments reported to CMS, 2019-2025
17 companies · $979 in 2025
The $979 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $133 · 2021: $169 · 2022: $279 · 2023: $647 · 2024: $441 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Education | $131.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,290.53 | 2019-2025 | |
| Boston Scientific Corporation | $790.01 | 2019-2025 | General - Biliary Devices, Overstitch Endoscopic Suturing System, Exalt Model D |
| Janssen Biotech, INC. | $266.41 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $162.49 | 2023-2025 | Entyvio |
| Olympus America INC. | $101.27 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.41 | 2020-2024 | Xifaxan |
| Pfizer INC. | $40.05 | 2019 | |
| Gilead Sciences, INC. | $33.57 | 2024 | |
| Genzyme Corporation | $19.62 | 2024 | |
| Merck Sharp & Dohme LLC | $18.16 | 2024 | Dificid |
| Celltrion USA INC. | $17.18 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $15.99 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $15.14 | 2025 | Voquezna |
| Alfasigma USA, INC. | $15.00 | 2020 | |
| Steris Corporation | $14.98 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.52 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Korman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.